Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. by Yee, Chee-Seng et al.
Title: Birmingham SLE Cohort: outcomes of a large inception cohort followed for up to 21 years

Authors: 	Dr Chee-Seng Yee
		Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, 
UK
		Dr Li Su
		MRC Biostatistics Unit, Cambridge, UK
		Dr Veronica Toescu
		University of Birmingham, Birmingham, UK
		Dr Richard Hickman
		University of Birmingham, Birmingham, UK
		Dr Deva Situnayake
		Sandwell and West Birmingham NHS Trust, Birmingham, UK
		Prof Simon Bowman
		Queen Elizabeth Hospital Birmingham, Birmingham, UK
		Prof Vernon Farewell
MRC Biostatistics Unit, Cambridge, UK
		Prof Caroline Gordon
		University of Birmingham, Birmingham, UK

Corresponding Author: Dr Chee-Seng Yee
                                      Consultant Rheumatologist
			  Doncaster and Bassetlaw Hospitals NHS Foundation Trust
			  Doncaster
                                      United Kingdom








This study describes the outcomes and predictors for development of damage in a large inception cohort of SLE patients.
Methods: 
This was a prospective longitudinal study of a cohort of SLE patients. SLE patients were included if they were recruited within 3 years of achieving the 4th ACR criterion for SLE. Data were collected on disease activity, damage and treatment. Information on death was provided by Office for National Statistics. The censoring date for analysis was 31/12/2010. A standardised mortality ratio (SMR) was calculated. Poisson regression was used to determine the incidence rate for damage accrual. Multi-state Markov modelling was used to determine predictors for development of damage.
Results: 
There were 382 patients (92.4% females, 51.6% Caucasian, 22% South Asian, 20.7% Afro-Caribbean) with 12072 assessments and total follow-up of 2958 patient-years. There were 300 items of damage (in 143 patients) and 37 deaths. The overall SMR was 2.0 (95% CI: 1.5, 2.8) and the commonest causes of death were: infection 37.8%, cardiovascular 27% and malignancy 13.5%. The predictors for damage accrual were higher prior damage, older age at diagnosis, active disease, systemic corticosteroid exposure and cyclophosphamide exposure. Patients were more likely to develop new damage earlier in their disease than later. Ethnicity was not predictive of damage accrual or death in this cohort.
Conclusions: 
























	Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease with significant morbidity and mortality. Outcomes in SLE can be described in three domains: disease activity which is reversible, damage which is not reversible and health-related quality of life [1]. Mortality is the ultimate form of damage and remains an important outcome measure. With improvement in the survival of SLE patients, other measures have become necessary to complement the mortality statistics and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index (SDI) is a validated measure of damage  ADDIN REFMGR.CITE [2]. This index measures damage that has developed since the diagnosis of SLE and this is regardless of attribution. 
	It is generally accepted that uncontrolled disease activity over time would result in damage. Nonetheless, the treatment of disease activity may in itself result in damage. Therefore, it would be incomplete to assess the relationship between disease activity and damage without including therapy in the analysis. There have been several studies previously looking at development of damage in SLE patients, especially in relation to disease activity and treatment  ADDIN REFMGR.CITE [3-17]. However, these studies have been hampered by several limitations. This type of analysis requires a longitudinal study but some of these studies are cross sectional which is inadequate  ADDIN REFMGR.CITE [6, 16, 17]. In addition, an inception cohort is essential for this type of study as this avoids the selection bias towards patients with milder disease and less damage, who would be more likely to survive to be recruited into the cohort. Apart from that, an inception cohort will minimise the effect of historical events that occurred prior to recruitment on the outcome of interest, which in itself is difficult to adjust for statistically. However, many previous studies were not been based on an inception cohort  ADDIN REFMGR.CITE [3, 6-9, 12-14, 16, 17]. Furthermore, many of these studies involved limited assessment of disease activity which is not an accurate representation of disease activity for the whole study period. In many studies, the assessment of disease activity was performed in study visits at set intervals (such as annually) which would not capture disease activity occurring between these visits. As a result, there is a tendency to underestimate disease activity as patients with more active disease would be far less likely to be able to attend these study visits  ADDIN REFMGR.CITE [4, 5, 10, 11, 13]. A large cohort of patients is required to enable a conclusive analysis to be performed but many previous studies had less than 200 patients  ADDIN REFMGR.CITE [8-10, 12-16].
	Here, we report on the outcomes (mortality and development of damage) from an inception SLE cohort from Birmingham with up to 21 years follow-up. In addition, we have performed a comprehensive assessment of the relationship between damage, disease activity and drug exposure. 

Methods
	This was a longitudinal study of the Birmingham SLE cohort that was set up in 1989, in which patients with SLE were under regular follow-up. This study received research ethical approval (from South Birmingham ethics committee) and written consent was obtained from all patients. It was carried out in accordance with the Helsinki Declaration.
	Patients were included if they were recruited within 3 years of achieving the fourth criterion of the revised ACR classification for SLE [18]. Data were collected prospectively on disease activity using the Classic BILAG index (every visit), treatment (every visit) and damage with SDI (at least every 12 months)  ADDIN REFMGR.CITE [2, 19, 20]. Information on death was obtained from the Office for National Statistics (ONS). The ONS is an independent national statistical institute for the UK and is responsible for collecting and publishing population statistics. It has mortality data going back to 1841.
	The censoring date for analysis was 31st December 2010. All statistical analyses were performed using Stata for Windows version 8 (Stata Corporation, College Station, Texas, USA) and R statistical software [21].

Mortality
	Descriptive statistics and standardised mortality ratio (SMR) calculations were used in the analysis of mortality in this cohort. SMRs were calculated using the mortality rates from general population of England and Wales which was specific for sex, age and calendar year. All deaths that occurred since recruitment into the cohort were included in the SMR calculations.

Predictors of death and damage
	For this longitudinal analysis, additional stringent criteria were applied for inclusion in the analysis. Patients had to be regularly followed up which was defined as a maximum of 13 months between visits. The data were censored if the interval between follow-up visits exceeded 13 months (44 patients in total had data censored). Death was included in the analysis if it occurred within 12 months of the last follow-up (6 deaths had to be censored). These additional exclusion criteria were required as the time lag was considered large, rendering the data on predictors (such as disease activity and medications) not very useful. 
	Poisson regression was used to determine the incidence rate of development of damage in this inception cohort. A non-reversible multi-state Markov model was used to examine transitions to different damage states as defined by SLICC/ACR damage index (SDI) score and death. As there were relatively few transitions to SDI scores of 5 to 8, these states were merged into a single state (SDI ≥ 5). Thus, there were 6 states in this model, as defined by the observed SDI scores of 0, 1, 2, 3, 4 and ≥ 5. Patients could only show deterioration in damage over their follow-up periods. From each of these 6 states, patients can also progress to death which is defined as the 'absorbing' state (see Figure A Supplementary Material). Multi-state modelling based on Markov processes enables estimation of transition rates between these observed states of damage and easily incorporates the effects of explanatory variables (both time-independent and time-dependent) on transition rates. The correlation among the states of a patient at different assessment visits is accounted for through the Markov assumption that the future evolution of the patient’s damage is dependent only on the current state and not on previous history of damage accrual. We examined the effects of various explanatory variables on the transition rates. Maximum likelihood estimates with confidence intervals for relative risks associated with the explanatory variables were reported.
	The time scale for this analysis was time since diagnosis in years. Multi-state modelling in this analysis was based on proportional hazards assumption and common explanatory variable effects on transition rates between different states. Another assumption was that the reference/baseline transition rates were constant over time. We found that it was reasonable to assume equal baseline transition rates for transitions from a non-zero SDI score to a higher SDI score (see Section B Supplementary Material). 
	For some analyses, we have combined Classic BILAG Grade A and Grade B scores in the individual systems to indicate active disease. Another alternative summary measure of disease activity used in the analysis was the number of systems with Grade A score and the number of systems with Grades A or B score, per assessment. 
	The variable on treatment used in the analyses was exposure to medications used to treat SLE (systemic corticosteroids, antimalarials, azathioprine, methotrexate, ciclosporin, cyclophosphamide, mycophenolate and rituximab) and was defined using 3 categories: 
1. No current or previous observed exposure (reference group)
2. No current use but with previous exposure (or previous exposure) 
3. Current exposure. 

For simplification, azathioprine, methotrexate and ciclosporin were grouped together as other immunosuppressives (separate from cyclophosphamide and mycophenolate).

Results
	There were 382 patients in this inception cohort with 12072 assessments and a total follow-up of 2958 patient years. The demographics of the cohort is summarised in Table 1. The number of patients exposed to medications used to treat SLE at any time during follow-up is also summarised in Table 1. The majority of patients (94.2%) did not have any damage at recruitment. However, there was a small number of patients (<0.1%) whose damage status were not known at recruitment as this occurred before the SDI had been validated. There were 702 systems with Grade A disease activity from 584 assessments (85.4% had only 1 system with Grade A) in 188 patients. The most common systems with Grade A activity were: musculoskeletal 23.4%, mucocutaneous 22.8%, renal 17.4%, neuropsychiatric 16.0%, vasculitis 8.0% and general 7.4%.

Mortality
	There were 37 deaths (9.7%) in this inception cohort (91.9% female, 67.6% Caucasian, 18.9% South Asian, 10.8 %Afro-Caribbean, 2.7% Chinese). The mean age at death was 53.7 years (SD 17.4) and mean disease duration at death was 6.9 years (SD 4.4). The causes of death were: infection 37.8%, cardiovascular 27.0%, malignancy 13.5%, acute respiratory distress syndrome 5.4%, active SLE 5.4%, pulmonary hypertension 2.7%, cardiac tamponade 2.7%, gastrointestinal bleed 2.7% and alcoholic liver cirrhosis 2.7%. The overall SMR was 2.0 (95% CI: 1.5, 2.8), with breakdown according to age group as shown in Table 2.

Development of Damage
	During follow-up, 300 items of damage developed in 143 (37.4%) patients. The distribution of damage was musculoskeletal 46.2%, neuropsychiatric 39.9%, ophthalmic 30.1%, renal 16.8%, cutaneous 14.7%, pulmonary 14.0%, cardiac 14.0%, gastrointestinal 10.5%, malignancy 9.8%, diabetes mellitus 6.3%, vascular 5.6% and premature menopause 2.1%. The overall rate of damage accrual for the cohort was 93.0 (95% CI: 79.6, 109.3) per 1000 person-years. The rates of development of damage over the follow-up period are summarised in Table 3. 

Predictors of Death and Damage
	For this analysis, only 31 of the 37 deaths met the stringent inclusion criteria. Therefore, there were too few deaths for a comprehensive analysis that would include all disease activity and medication variables in the model for transitions to death. However, we did find that having damage (SDI ≥ 1) were associated with increased risk of death as compared to those who did not have damage (Table 4 and Table A in Supplementary Material). There was no association between ethnicity and death (data not shown). In the initial fitting of the Markov model to estimate transition rates between different damage states, we found that higher current SDI scores were associated with higher probability of accruing more damage (Table A in Supplementary Material). This is reflected in Table 4 where the probability of increase in damage in 5 years was higher if starting from a higher damage state (see the diagonal line of Table 4: 0.201, 0.261, 0.349, 0.384, 0.392). This relationship was statistically significant (p<0.0001) using a likelihood ratio test when the trend was modelled as a quadratic relationship with current SDI state.
	Regression analyses were used to assess the effect of demographic variables, disease activity and drug exposure (systemic corticosteroids, antimalarials, immunosuppressives and rituximab) on damage accrual (transition to higher damage score). Two separate models were fitted as two separate measures of disease activity were used in the analyses (Tables 5 and 6).
	In the multivariate analyses, we found the number of systems with Grade A or B (indicating active disease) to be significantly associated with development of more damage, especially with Grade A or B activity in Neuropsychiatric and Renal systems. Independent of disease activity, exposure to systemic corticosteroids (current exposure) and cyclophosphamide (both current and previous exposures) were associated with worse damage outcome. Patients appeared to be more likely to develop damage in earlier stage in their disease  (disease duration ≤ 5 years) than later (disease duration > 5 years). The effect of rituximab was not estimable as there were only 18 patients who had exposure to rituximab and none of them developed further damage following treatment. However, univariate analysis with simple cross tabulation did not show a significant protective effect of rituximab against damage accrual (Fisher exact test, p=0.41).
	We also assessed the possibility of interactions between active disease (Grade A or B) in Renal and Neuropsychiatric systems with cyclophosphamide exposure. There was no significant interaction between Grade A or B activity in Renal system and cyclophosphamide exposure (p=0.575). However, there was statistically significant interaction between Grade A or B activity in Neuropsychiatric system and cyclophosphamide exposure (p=0.03). For patients without Grade A or B activity in Neuropsychiatric system, current exposure (Hazard Ratio (HR) = 4.05, 95% CI: 2.36,  6.95) or previous exposure to cyclophosphamide (HR= 2.26, 95% CI: 1.53,  3.34)  were associated with more damage accrual. However, the risk for further damage was lowered in patients with Grade A or B activity in Neuropsychiatric system if they had current (HR = 4.7, 95% CI: 1.1, 20.1) or previous (HR = 3.64, 95% CI: 0.9, 15.7) exposures to cyclophosphamide as compared to those without exposure to cyclophosphamide (HR = 6.3, 95% CI: 3.3, 11.8). Note that the hazard ratios were relative to the reference group of patients without Grade A or B activity in Neuropsychiatric system and without current or previous exposure to cyclophosphamide.
 
Discussion 
	We have presented the outcomes of a large inception cohort of SLE patients, looking at mortality and development of damage over a long period of follow-up (up to 21 years) in a single centre in the UK. There is shorter life expectancy as compared to the general population and this is in keeping with the results of  previous studies  ADDIN REFMGR.CITE [22-24]. This is most apparent in the younger age group. On average, the mean age at death for this cohort is at least 20 years less than the mean age of death for England and Wales. As with previous studies, the common causes of death were infection, cardiovascular diseases and malignancy. The damage accrual rate appears to be lower than the Hopkins Lupus cohort of 130 per 1000 person-years  ADDIN REFMGR.CITE [3]. This difference might be due to different ethnic and socio-economic background of patients between the two cohorts. In addition, Poisson regression was used to estimate the incidence of damage in this study while mean damage accrual rates were reported in the Hopkins Lupus cohort.
	In this study, we performed a comprehensive longitudinal assessment of the relationship between damage accrual, disease activity and therapy. We found that active disease was associated with development of more damage, even after adjusting for treatment and previous damage. In addition, exposure to cyclophosphamide and systemic corticosteroids were independently associated development of damage, after adjusting for disease activity. 
	There have been conflicting data with regards to association of damage accrual with disease activity and systemic corticosteroids. Some studies found both disease activity and systemic corticosteroids to be associated with damage accrual
  ADDIN REFMGR.CITE [4-6, 10, 17] while others found either only disease activity or systemic corticosteroids to be associated  ADDIN REFMGR.CITE [3, 6, 7, 9, 11, 13, 25]. One of the main reasons for these differences amongst the studies might be due to different study designs used. The majority of these studies have major limitations as they are not based on analysis of an inception cohort, with the exception of the LUMINA cohort  ADDIN REFMGR.CITE [10, 26, 27], and some of the studies involve cross sectional analysis  ADDIN REFMGR.CITE [6, 17, 25]. Apart from that, some studies used limited assessment of disease activity such as the use of disease activity over a period of 12 months initially  ADDIN REFMGR.CITE [7] or disease activity at certain set time points (such as at diagnosis, at recruitment or annually)  ADDIN REFMGR.CITE [4, 5, 10, 11]. The use of these limited assessments of disease activity does not accurately reflect disease activity for the whole study period. For studies in which the assessments were performed at study visits with set time points, they would fail to capture disease activity occurring between these visits and it might bias towards patients with less active disease, as patients with more active disease might be less likely to attend these study visits (due to feeling too unwell to undergo extensive study assessment). This could lead to a tendency of underestimating disease activity in such studies. In addition, different disease activity measures (Classic BILAG vs SLAM vs SLEDAI) have been used in different studies which might contribute to the varying conclusions. Given the strengths of our study in being an inception cohort with long follow-up and the comprehensive statistical model used in the analysis, we believe that our results provide convincing evidence that both active disease and systemic corticosteroids are associated with worse damage outcomes. It is not surprising that active disease in Neuropsychiatric and Renal systems are associated with development of damage as manifestations in these two systems (such as nephritis, myelopathy, seizures and neuropathy) are consistent with severe disease.
	Surprisingly, many previous studies have not borne out the same effect of cyclophosphamide on damage accrual as observed here. This may reflect the low usage of this treatment modality in some centres, especially with the advent of mycophenolate and rituximab. Analysis of the LUMINA cohort did show a significant association between the use of cytotoxics and osteonecrosis  ADDIN REFMGR.CITE [28]. Another large cross sectional study in Canada showed a strong association between damage and cyclophosphamide usage  ADDIN REFMGR.CITE [17]. Interestingly, treatment with cyclophosphamide is associated with lower risk of further damage in patients with active disease in Neuropsychiatric system. This probably reflects the double-edged sword nature of cyclophosphamide in which it causes damage but is also effective in controlling severe active SLE manifestations and preventing damage as a result.
	In contrast to cyclophosphamide, mycophenolate and other immunosuppressives are not associated with increased risk of damage. In fact, there is a trend towards reduced risk of damage which perhaps reflects steroid-sparing properties. Similarly, the use of rituximab appears to halt the development of damage. In this cohort, rituximab is used in patients with the most severe disease who have failed conventional immunosuppressives and/or cytotoxic therapy. It might have been expected that this group of patients would have been at high risk of developing further damage. However, our analysis of rituximab is based on a small number of patients and rituximab has only been in used for about 8 years at the time of this analysis. A longer follow-up period and a larger number of patients would be required to confirm this finding.
	Another finding is that patients were more likely to develop damage earlier in their disease than later. It is possible that high disease activity coupled with less established therapy resulted in higher damage accrual in early disease while adequate disease control with reduction in corticosteroids over time resulted in slower damage accrual in later stages of the disease. ADDIN REFMGR.CITE [29, 30] This finding deserves further investigation. 
	We have not observed an association of ethnicity with  development of damage, after adjusting for disease activity, previous damage and therapy. This is similar to the results of other recent studies from North America and Europe  ADDIN REFMGR.CITE [3, 7, 17]. The association of ethnicity with damage in some studies might be explained by clinical (disease activity, previous damage and treatment) and socioeconomic factors (which includes education status, income and access to healthcare). One possible reason for the lack of association between ethnicity and damage accrual in our cohort and a previous study in UK  ADDIN REFMGR.CITE [7] is that the healthcare system in the United Kingdom provides for equal access to everyone.
	One of the limitations of this study is the unavailability of cumulative dose of exposure to the medications of interest. It is likely that cyclophosphamide and systemic corticosteroids would have some dose dependent effect. Apart from that, the inception cohort of this study is defined by recruitment within 3 years of achieving the 4th ACR criterion for SLE. Ideally, a shorter lag time (such as within a year of achieving the 4th criterion) would be more robust but this would significantly affect the number of patients available for this study. A lag time of 3 years was chosen as a signicant number of patients were not referred and diagnosed until a few years after fulfilling 4 ACR criteria for SLE.  It is possible that some patients were missed that had severe early disease that had not been diagnosed as SLE and so had not had the opportunity to be referred and recruited.
	In summary, this study has demonstrated that active disease, systemic corticosteroids and cyclophosphamide are associated with development of more damage. As damage is associated with development of further damage and mortality, it is crucial to prevent and minimise the development of damage. Therefore, active disease in SLE patients needs to be treated and brought under control promptly but with judicious use of systemic corticosteroids and cyclophosphamide.

Key Messages:
1. Active disease, corticosteroid exposure and cyclophosphamide exposure were independently associated with development of damage.
2. Patients were more likely to develop new damage earlier in their disease than later.
3. SLE patients have premature mortality with infection, cardiovascular disease and malignancy being the commonest causes.
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Ethnic group  Caucasian  Afro-Caribbean  South Asian  Chinese  Others	197 (51.6%)79 (20.7%)86 (22.0%)9 (2.4%)13 (3.4%)
Mean age at recruitment (SD)	36.3 (13.3)
SDI at recruitment   0   1   2   unknown	360 (94.2%)18 (4.7%)3 (< 0.1%)1 (< 0.1%)
Duration of follow-up  Mean (SD)  Range (years)	7.7 years (5.2)0.2 – 21.3




Table 2. Standardised mortality ratio by age group

Age group (years)	SMR (95% CI)
20 - 24	5.2 (1.3, 20.9)
25 – 34	3.5 (1.3, 9.3)
35 – 44	2.4 (1.0, 5.8)
45 – 54	3.0 (1.6, 5.7)
55 – 64	1.2 (0.5, 2.9)
65 – 74	2.5 (1.3, 4.7)
75 – 84	1.0 (0.2, 3.8)





Table 3. Incidence rate of development of damage over period of follow-up at 3 yearly intervals

Period of follow-up (year)	Person-years at risk	Number of new items of damage	Incidence rate, per 1000 person-years(95% CI)
0 – 3	1043.3	125	119.8 (98.1, 147.9)
3 – 6	779.1	67	86.0 (65.7, 114.7)
6 – 9	499.0	35	70.1 (48.9, 104.4)
9 – 12	322.4	28	86.8 (61.3, 127.2)
12 – 15	191.7	9	47.0 (24.1, 104.6)
15 – 18	86.5	6	69.4 (19.6, 411.8)





Table 4. Predicted probability of a patient's SDI score or death in 5 year's time (conditional on current SDI score)
Original State	Destination State











Table 5. Multivariate regression analysis on transition to higher damage using individual system scores of Classic BILAG index.
Variable	HR (95% CI)
Male sex	0.66 (0.41, 1.07)
Ethnicity    Caucasian     Afro-Caribbean    South Asian    Others	1 (reference group)0.91 (0.62, 1.33)1.12 (0.80, 1.57)1.09 (0.59, 2.01)
Age at diagnosis (standardised to age of 35 years and per 12 years)	1.55 (1.37, 1.76)
Disease duration    < 5 years    5 to 10 years    > 10 years	1 (reference group)0.66 (0.48, 0.92)0.48 (0.31, 0.74)
Classic BILAG Activity       General A or B       Neuropsychiatric A or B       Mucocutaneous A or B       Musculoskeletal A or B       Cardiorespiratory A or B       Vasculitis A or B       Renal A or B       Haematology A or B	1.15 (0.49, 2.68)3.47 (1.97, 6.13)1.33 (0.86, 2.05)1.24 (0.85, 1.81)0.20 (0.03, 1.56)1.29 (0.51, 3.25)2.79 (1.72, 4.54)0.57 (0.23, 1.43)
Medication exposure       Hydroxychloroquine - current use       Hydroxychloroquine - previous use       Corticosteroids (systemic) - current use       Corticosteroids (systemic) - previous use                           Cyclophosphamide - current use       Cyclophosphamide - previous use       Mycophenolate - current use       Mycophenolate - previous use      Other immunosuppressives - current use      Other immunosuppressives - previous use      Rituximab - current use      Rituximab - previous use	0.83 (0.61, 1.15)1.12 (0.76, 1.64)2.46 (1.50, 4.04)1.58 (0.82, 3.02)3.40 (2.02, 5.73)2.11 (1.43, 3.100.59 (0.32, 1.10)0.96 (0.48, 1.92)0.80 (0.57, 1.14)1.09 (0.71, 1.67)Not estimable0.52 (0.18, 1.45)

* significant association highlighted in bold


Table 6. Multivariate regression analysis on transition to higher damage using alternative summary disease activity measure of Classic BILAG index.
Variable	HR (95% CI)
Male sex	0.64 (0.39, 1.03)
Ethnicity    Caucasian     Afro-Caribbean    South Asian    Others	1 (reference group)0.99 (0.68, 1.44)1.12 (0.80, 1.57)1.08 (0.59, 2.00)
Age at diagnosis (standardised to age of 35 years and per 12 years)	1.51 (1.33, 1.72)
Disease duration    < 5 years    5 to 10 years    > 10 years	1 (reference group)0.65 (0.47, 0.90)0.46 (0.30, 0.71)
Classic BILAG Activity    Number of systems with Grade A    Number of systems with Grade A or B	0.95 (0.66, 1.37)1.34 (1.09, 1.63)
Medication exposure       Hydroxychloroquine - current use       Hydroxychloroquine - previous use       Corticosteroids (systemic) - current use       Corticosteroids (systemic) - previous use                           Cyclophosphamide - current use       Cyclophosphamide - previous use       Mycophenolate - current use       Mycophenolate - previous use      Other immunosuppressives - current use      Other immunosuppressives - previous use      Rituximab - current use      Rituximab - previous use	0.79 (0.58, 1.08)1.14 (0.78, 1.67)2.41 (1.47, 3.97)1.57 (0.82, 3.00)3.54 (2.08, 6.03)2.11 (1.44, 3.08)0.59 (0.32, 1.09)0.98 (0.49, 1.94)0.77 (0.55, 1.10)1.13 (0.74, 1.73)Not estimable0.60 (0.22, 1.66)

* significant association highlighted in bold




PAGE  



16



